RXI-231 may represent a promising approach to the treatment of hyperpigmentation, according to research in Clinical, Cosmetic and Investigational Dermatology.
Phio Pharmaceuticals Corp’s RXI-231 is an INTASYL compound designed to target and reduce tyrosinase (TYR) gene expression. INTASYL siRNA gene silencing technology is designed to make the body’s immune cells more effective in killing cancer cells.
RXI-231 significantly reduced tyrosinase mRNA expression, and correspondingly reduced in melanin content in both normal human melanocytes and the 3D human epidermal culture, Melano Derm model, the new study showed.
Application of INTASYL RXI-231 every other day visibly reduced pigmentation in the 3D epidermal cultures. RXI-231 was also evaluated using the MatTek EpiDerm Skin Irritation model which confirmed its non-irritant profile. While further characterization and clinical testing is needed, RXI-231 shows promise in treating hyperpigmentation disorders, the study authors report.
“We are delighted to see this publication which presents a summary of INTASYL compound RXI-231’s uniqueness in addressing its selective targeting of TYR gene expression, and underscores the innovative and expansive potential of INTASYL compounds in dermatological conditions,” says Robert Bitterman, CEO of Phio Pharmaceuticals, in a news release.
